Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Organon & Co. (NYSE: OGN) provide detailed, regulatory-grade insight into the operations of a global healthcare company focused on Women’s Health, General Medicines and biosimilars. Through current reports on Form 8-K and related amendments, Organon discloses quarterly earnings information, leadership changes, governance matters and the status of internal controls over financial reporting.
Recent 8-K filings furnish earnings releases for quarters such as the period ended June 30, 2025 and September 30, 2025, along with investor presentations that discuss revenue by segment, non-GAAP measures like Adjusted EBITDA and Adjusted gross margin, and capital allocation decisions including dividends. These filings help readers understand how Organon’s women’s health, biosimilars and established brands portfolios contribute to overall performance.
Other 8-Ks and an 8-K/A detail material governance events, including the resignation of the Chief Executive Officer, the appointment of an Interim Chief Executive Officer and an Executive Chair, and compensation arrangements for these roles. Filings also summarize the Audit Committee investigation into wholesaler sales practices for Nexplanon, the determination that certain practices were improper, and the conclusion that previously issued financial statements do not require restatement, while management’s prior assessment of internal control effectiveness must be revised.
On this page, users can review Organon’s SEC disclosures alongside AI-powered summaries that clarify the significance of each document. Filings such as earnings 8-Ks, future annual reports on Form 10-K, quarterly reports on Form 10-Q and any proxy or insider transaction reports can be examined to track segment performance, internal control remediation, leadership structure and other regulatory matters. Real-time updates from EDGAR combined with AI explanations can help investors and researchers interpret complex language, identify key risk and governance themes, and follow Organon’s ongoing reporting obligations.
Organon & Co. Chief Information Officer Rachel A. Stahler exercised restricted stock units into common shares and had a portion withheld for taxes. On March 29, 2026, 8,200 restricted stock units converted into 8,200 shares of common stock, reflecting equity compensation vesting.
To cover tax obligations, 2,809 of those shares were automatically withheld at a price of $5.84 per share, rather than sold in the open market. After these routine compensation and tax-withholding transactions, Stahler directly held 103,701.292 shares of Organon common stock.
Organon & Co. SVP and Corporate Controller Lynette Holzbaur exercised 5,319 restricted stock units into common stock. Each RSU converted into one share, reflecting a scheduled vesting installment. Of the shares received, 1,516 were withheld at $5.84 per share to cover tax obligations.
After these transactions and the addition of 82 shares from dividend equivalents, Holzbaur directly holds 18,561.427 shares of Organon common stock. The activity represents routine equity compensation, combining an RSU vesting event with share withholding for taxes rather than an open‑market trade.
Organon & Co. Executive VP, Corp. Dev. Daniel Karp exercised 14,184 Restricted Stock Units into common stock. The RSUs converted one-for-one into Organon shares at a stated price of $0.00 per unit.
To satisfy tax obligations, 4,446 shares of common stock were withheld at a reference price of $5.84 per share, based on the closing market price on March 27, 2026 as required under the plan. Following these transactions, Karp directly holds 57,153.923 shares of Organon common stock, which includes 746.463 shares acquired from dividend equivalents net of withholding tax. The RSUs vest and are distributed in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Organon & Co. general counsel Kirke Weaver exercised restricted stock units into common shares and had shares withheld for taxes. On March 29, 2026, 7,757 restricted stock units converted into 7,757 common shares at a stated price of $0.00 per share. Of these, 2,210 common shares were withheld at $5.84 per share to satisfy tax obligations, a non-market transaction. After these transactions, Weaver directly holds 79,401.163 shares of Organon common stock. The footnotes state each RSU represents one share of common stock and that this RSU award vests in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Organon & Co. executive Nisita Vittorio exercised 5,762 Restricted Stock Units (RSUs) into common stock and covered taxes with shares. Each RSU converts into one share of Organon common stock. After these transactions, Vittorio directly holds 62,072.158 shares of Organon common stock.
A total of 1,974 common shares were withheld at a price of $5.84 per share to satisfy tax obligations, which is treated as a tax-withholding disposition rather than an open-market sale. The RSUs vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027, aligning share delivery with the executive’s multi‑year compensation schedule.
Organon & Co.'s Interim Head of Manufacturing & Supply, Juliana Papa Drinane, exercised 7,979 Restricted Stock Units into common stock on March 29, 2026. To cover taxes, 2,733 shares were withheld at $5.84 per share. She now directly holds 22,420.703 Organon common shares, reflecting a routine compensation-related equity increase.
Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira exercised restricted stock units into common shares as part of equity compensation. On March 29, 2026, 8,865 RSUs converted into 8,865 shares of common stock at a stated price of $0.00 per share.
To satisfy tax obligations, 3,181 common shares were withheld at $5.84 per share, a non‑market disposition rather than an open‑market sale. After these transactions, he directly holds 21,436.477 common shares. Beneficial ownership was also adjusted to reflect a prior transfer of 13,872 shares under Exchange Act Rule 16a-12 and the addition of 708.122 shares from dividend equivalents.
Organon & Co. Chief Human Resources Officer Aaron Falcione exercised restricted stock units into common shares as part of his equity compensation. On March 29, 2026, 8,422 Restricted Stock Units converted into 8,422 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations, 2,885 of these shares were disposed of through a tax-withholding transaction at $5.84 per share, rather than through an open-market sale. After these transactions, Falcione directly held 89,646.071 shares of Organon common stock.
Each Restricted Stock Unit represents a right to receive one share of Organon common stock, and these awards vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027, aligning the executive’s compensation with the company’s long-term performance.
Organon & Co. Chief Financial Officer Matthew M. Walsh exercised restricted stock units into common shares and had some shares withheld for taxes. On March 29, 2026, 15,071 restricted stock units converted into 15,071 shares of Organon common stock at a stated price of $0.00 per share.
To cover tax obligations, 5,162 of these common shares were withheld at a price of $5.84 per share. After these compensation-related transactions, Walsh directly owned 190,660 shares of Organon common stock. The underlying restricted stock units vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Organon & Co. interim CEO Joseph T. Morrissey Jr. exercised 9,752 Restricted Stock Units (RSUs) into common stock on March 29, 2026. Each RSU converts into one share of Organon common stock, and the award vests in three equal installments on March 29, 2025, 2026, and 2027. To satisfy tax obligations related to this vesting, 2,779 common shares were withheld at a reference price of $5.84 per share. After these compensation-related transactions, Morrissey holds 105,543.923 common shares directly, indicating this filing reflects routine equity award vesting and associated tax withholding rather than an open-market stock sale.